Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
T

TECH

Nasdaq

BIO-TECHNE Corp

Latest disclosureSeptember 30, 2026
Insider score Why 0?
0/ 100
Qualifying buys · 30d
$0

0 purchases · 1 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 98

Limited filing history
All98Buying0Selling1Other97
Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

97 of 98 trades · April 3, 2026 – September 28, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 20 trades on this page.

Exercise or conversion

John L. Higgins

Director

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded September 28, 2026Filed September 30, 2026SEC filing
Tax or exercise withholding

John L. Higgins

Director

Common Stock

Value context
$403.3K
Reported price
$72.51 / share
Traded September 28, 2026Filed September 30, 2026SEC filing
Exercise or conversion

John L. Higgins

Director

Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$25.30 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded September 28, 2026Filed September 30, 2026SEC filing
Exercise or conversion

Robert V. Baumgartner

Director

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded September 22, 2026Filed September 24, 2026SEC filing
Tax or exercise withholding

Robert V. Baumgartner

Director

Common Stock

Value context
$403.31K
Reported price
$72.55 / share
Traded September 22, 2026Filed September 24, 2026SEC filing
Exercise or conversion

Robert V. Baumgartner

Director

Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$25.30 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded September 22, 2026Filed September 24, 2026SEC filing
Award disclosed

Shane Bohnen

SVP - General Counsel

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Shane Bohnen

SVP - General Counsel

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Kim Kelderman

Chief Executive Officer

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Kim Kelderman

Chief Executive Officer

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

James Hippel

CFO

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

James Hippel

CFO

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Amy E. Herr

Director

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

William Geist

PRESIDENT, PROTEIN SCIENCES

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

William Geist

PRESIDENT, PROTEIN SCIENCES

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Steven C. Crouse

President - Diag & Spatial Bi

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Award disclosed

Steven C. Crouse

President - Diag & Spatial Bi

Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 17, 2026Filed August 19, 2026SEC filing
Exercise or conversion

Kim Kelderman

Chief Executive Officer

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded August 15, 2026Filed August 18, 2026SEC filing
Tax or exercise withholding

Kim Kelderman

Chief Executive Officer

Common Stock

Value context
$783.44K
Reported price
$72.40 / share
Traded August 15, 2026Filed August 18, 2026SEC filing
Exercise or conversion

Kim Kelderman

Chief Executive Officer

Performance Restricted Stock Units

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 15, 2026Filed August 18, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
DirectorCommon StockOption exercise or conversion15,940$0 reported · see filingNot establishedSep 28Filed Sep 30 · 2d laterSEC filing
DirectorCommon StockExercise-price or tax withholding5,562$72.51 / share$403.3KSep 28Filed Sep 30 · 2d laterSEC filing
DirectorStock Options (Right to Buy)Option exercise or conversionDerivative units15,940$25.30 exercise / conversion priceNot a separate purchaseSep 28Filed Sep 30 · 2d laterSEC filing
DirectorCommon StockOption exercise or conversion15,940$0 reported · see filingNot establishedSep 22Filed Sep 24 · 2d laterSEC filing
DirectorCommon StockExercise-price or tax withholding5,559$72.55 / share$403.31KSep 22Filed Sep 24 · 2d laterSEC filing
DirectorStock Options (Right to Buy)Option exercise or conversionDerivative units15,940$25.30 exercise / conversion priceNot a separate purchaseSep 22Filed Sep 24 · 2d laterSEC filing
SVP - General CounselRestricted Stock UnitsGrant or awardDerivative units11,344Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
SVP - General CounselRestricted Stock UnitsGrant or awardDerivative units18,432Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
Chief Executive OfficerRestricted Stock UnitsGrant or awardDerivative units57,590Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
Chief Executive OfficerRestricted Stock UnitsGrant or awardDerivative units93,582Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
CFORestricted Stock UnitsGrant or awardDerivative units22,438Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
CFORestricted Stock UnitsGrant or awardDerivative units36,459Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
DirectorRestricted Stock UnitsGrant or awardDerivative units1,381Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
PRESIDENT, PROTEIN SCIENCESRestricted Stock UnitsGrant or awardDerivative units14,762Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
PRESIDENT, PROTEIN SCIENCESRestricted Stock UnitsGrant or awardDerivative units23,985Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
President - Diag & Spatial BiRestricted Stock UnitsGrant or awardDerivative units8,702Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
President - Diag & Spatial BiRestricted Stock UnitsGrant or awardDerivative units14,140Award · no purchase priceNon-cash awardAug 17Filed Aug 19 · 2d laterSEC filing
Chief Executive OfficerCommon StockOption exercise or conversion21,470$0 reported · see filingNot establishedAug 15Filed Aug 18 · 3d laterSEC filing
Chief Executive OfficerCommon StockExercise-price or tax withholding10,821$72.40 / share$783.44KAug 15Filed Aug 18 · 3d laterSEC filing
Chief Executive OfficerPerformance Restricted Stock UnitsOption exercise or conversionDerivative units554Exercise / conversion price not reportedNot a separate purchaseAug 15Filed Aug 18 · 3d laterSEC filing

Showing the latest 20 of 97 trades. Show all 97 trades

Congress transactions 7

All Congress filings
Sale disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a sale for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
April 8, 2026
Filed May 6, 2026 · 28d laterOriginal report
Partial sale disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a partial sale for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
March 26, 2026
Filed April 6, 2026 · 11d laterOriginal report
Partial sale disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a partial sale for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
February 24, 2026
Filed March 10, 2026 · 14d laterOriginal report
Partial sale disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a partial sale for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
January 28, 2026
Filed February 2, 2026 · 5d laterOriginal report
Purchase disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a purchase for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
December 5, 2025
Filed January 5, 2026 · 31d laterOriginal report
Purchase disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a purchase for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
December 2, 2025
Filed January 5, 2026 · 34d laterOriginal report
Purchase disclosed

Bio-Techne Corp - Common Stock (TECH) · Stock

The filing reports a purchase for a dependent.

April McClain Delaney official portraitApril McClain DelaneyReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
October 22, 2025
Filed November 4, 2025 · 13d laterOriginal report
Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0000842023
Latest public acceptance
Sep 30, 2026, 08:13 PM UTC
Score calculated
Oct 8, 2026, 12:04 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.